Gerresheimer stock steadies around 28 euros as AGM and fresh analyst views shape the outlook
Published on 09/01/2026 at 17:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gerresheimer AG (ISIN DE000A0LD6E6) stock is trading around the 28-euro mark as of September 1, 2026, with recent data showing a last Xetra closing price of 28.12 euros and intraday indications near 27.50 euros on Tradegate on the same date.
AGM on September 1, 2026 sets the agenda
The company is holding its annual general meeting virtually on September 1, 2026 at 10:00 a.m. Central European Summer Time, a key date for investors watching capital allocation and strategic priorities for the new financial year.
According to a current AGM notice compiled by EQS News, shareholders will follow the meeting online, with details and agenda documents available via the company website. The timing of the AGM, coming shortly after the start of the new financial year, underlines management’s focus on explaining the path for earnings and cash flow in 2026.
Q1 2026 figures frame the financial year
For the fundamental picture, the most recent reported quarter is Q1 2026, which falls well within the recency window for current figures and therefore provides the main baseline for evaluating Gerresheimer stock.
Per a recent market overview dated August 28, 2026, Gerresheimer posted preliminary Q1 2026 revenue of 524 million euros, starting the financial year on a solid footing after the prior year.Corporate news summaries highlight that this revenue level, achieved in the first quarter of the new fiscal year, anchors expectations for the rest of 2026.
On profitability, the same Q1 2026 snapshot points to adjusted EBITDA of 66 million euros, indicating that the company is converting a meaningful share of its sales into operating earnings early in the year.The same overview shows that these figures are being used by the market as a benchmark heading into the AGM window.
Investors will be looking closely at how management links the Q1 2026 numbers to guidance for the full year, including margin trends and capital expenditure for capacity and technology. With revenue at 524 million euros and adjusted EBITDA at 66 million euros in Q1 2026, Gerresheimer is entering the new year with a combination of scale and profitability that supports medium-term investment plans.
Analyst views and price targets around the 30-euro level
Alongside the AGM and Q1 2026 figures, the analyst view provides another important lens for Gerresheimer stock on September 1, 2026.
According to a recent analyst consensus compiled by finanzen.ch and dated August 31, 2026, the average price target for Gerresheimer shares stands at 30.43 euros. With the current Xetra price at 28.12 euros as of late August 2026, this implies upside potential of 2.31 euros, or about 8.2 percent, if the consensus scenario materializes.
The same consensus snapshot indicates that analysts see room for moderate appreciation rather than a sharp re-rating, reflecting a balance of earnings stability and valuation constraints.
In addition, a rating update reported by finanzen.at shows that JP Morgan keeps Gerresheimer at an Overweight rating as of September 1, 2026, with a current market price of 27.84 euros cited in the analysis. The distance between this trading level and the bank’s higher price target, described in the same report, suggests that at least one major institution expects the stock to outperform the wider market over time.
Separate data from MarketScreener’s German and Belgian portals on September 1, 2026 point to intraday Tradegate prices around 27.36 to 27.51 euros, with five-day performance modestly negative but year-to-date changes also slightly in the red.These intraday snapshots underline that the stock is currently consolidating rather than trending strongly in either direction.
Gerresheimer stock in detail
For more structured updates on Gerresheimer stock, including intraday price moves, news and background information, the dedicated topic page bundles recent coverage.
Primary packaging for pharmaceuticals as a core business
Operationally, Gerresheimer is best known as a specialist in primary packaging for the pharmaceutical and healthcare industries, supplying products such as glass vials, ampoules, syringes and plastic containers.
One representative product category is sterile glass vials used for injectable medicines and vaccines, which form part of the company’s so-called primary packaging solutions. These vials, together with related closures and delivery systems, are sold to pharmaceutical companies worldwide and contribute significantly to revenue in the plastics and devices as well as glass packaging segments.
While current sources in this search call do not break down the latest quarter by product line in detail, previous corporate presentations have highlighted that high-value pharmaceutical packaging and medical devices are central to Gerresheimer’s strategy of driving margin-accretive growth and differentiating itself from generic packaging providers.
Stock trades near recent levels on Xetra and Tradegate
From a market perspective, Gerresheimer shares are listed in Germany and form part of the MDAX index, giving the stock a notable role in the country’s mid-cap segment.
As of late August 2026, a recent German-market overview reports a Tradegate price of 26.50 euros for Gerresheimer AG at 10:25 p.m. Eastern Time on August 28, 2026, with a modest gain of 0.15 percent on the day.This closing marker serves as a useful reference when comparing current levels around 27.36 to 27.51 euros on Tradegate on September 1, 2026.
Using the Xetra closing level of 28.12 euros cited in recent analyst overviews as a baseline, the current consensus price target of 30.43 euros implies about 8.2 percent upside, while the stock’s slight negative performance over the last five trading days shows that the market is taking a cautious stance ahead of the AGM and further guidance.
Gerresheimer stock facts
- Company: Gerresheimer AG
- ISIN: DE000A0LD6E6
- WKN: A0LD6E
- Ticker: GXI
- Trading venue: Xetra (primary listing), Tradegate
- Price (as of August 28, 2026, 10:25 p.m.): 26.50 EUR
- Market capitalization: Market data overviews place Gerresheimer in the mid-cap range in the MDAX (as of August 28, 2026)
- Sector / Industry: Health care, pharmaceutical packaging
- Index membership: MDAX
